Sort
51,593 grants matching “hepatitis”
New generation of long acting nucleos(t)ides and immune stimulant for treatment of chronic hepatitis B
$611,174Larisa Y Poluektova · University Of Nebraska Medical Center · R01 · FY2024 · AI
New generation of long acting nucleos(t)ides and immune stimulant for treatment of chronic hepatitis B
$611,174Larisa Y Poluektova · University Of Nebraska Medical Center · R01 · FY2023 · AI
New generation of long acting nucleos(t)ides and immune stimulant for treatment of chronic hepatitis B
$611,174Natalia Aleksandr Osna · University Of Nebraska Medical Center · R01 · FY2025 · AI
Enhanced Anti-HIV-1 Antibody Responses in African American Women Seropositive for
$611,087Phillip Berman · University Of California Santa Cruz · R01 · FY2013 · DA
Launching HBV with RNA to assess antiviral resistance and explore fundamental aspects of virus-host biology
$611,076Charles M. Rice · Rockefeller University · R01 · FY2023 · AI
Launching HBV with RNA to assess antiviral resistance and explore fundamental aspects of virus-host biology
$611,076Charles M. Rice · Rockefeller University · R01 · FY2024 · AI
Molecular and Cellular Basis of PCB Developmental Neurotoxicity
$611,064Pamela J Lein · University Of California At Davis · R01 · FY2024 · ES
Physiological Ramifications of Chorionic Somatomammotropin Deficiency
$611,060Paul Joseph Rozance · University Of Colorado Denver · R01 · FY2018 · HD
HIV/HCV Co-infection: HAART and CVD Pathophysiology
$611,050Barry E. Hurwitz · University Of Miami Coral Gables · R01 · FY2006 · HL
Kidney Health Biomarker Panels for Drug Toxicity and Prognosis in HIV Infection
$610,991Michael G Shlipak · Northern California Institute/Res/Edu · R01 · FY2019 · AG
Developmental pathways, environmental agents, and epigenetics in liver disease
$610,974Keith D Robertson · Augusta University · R01 · FY2012 · AA
HCC Risk Stratification in MAFLD Cirrhosis
$610,853Hashem B El-Serag · Baylor College Of Medicine · P01 · FY2022 · CA
GB Virus type C Natural History, Epidemiology, HIV Interaction
$610,851Jack T Stapleton · University Of Iowa · R01 · FY2007 · AI
Persistent hepatitis C virus replication and T cell immunity in pregnancy
$610,754Christopher M. Walker · Research Inst Nationwide Children'S Hosp · R56 · FY2011 · AI
Impact of harm reduction care in HIV clinical settings on stigma and health outcomes for PLWH who use drugs
$610,732Mary Elizabeth Hawk · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · DA
CETP and HDL Function in Cardiovascular Diseases
$610,711Yuqing E Chen · University Of Michigan At Ann Arbor · R01 · FY2015 · HL
THE DINUCLEOTIDE SB-9000 A NOVEL ANTI-HBV AGENT
$610,629Radhakrishnan P Iyer · Spring Bank Technologies, Inc. · U01 · FY2007 · AI
Dendritic cell-based vaccination against hepatitis C
$610,608Stephen H. Gregory · University Of Rhode Island · U19 · FY2010 · AI
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
$610,603Brad Kahl · University Of Wisconsin-Madison · U10 · FY2008 · CA
Mental Health and Cognition in HIV Infection in Rakai Uganda
$610,528Ned C Sacktor · Johns Hopkins University · R01 · FY2019 · MH
New generation of long acting nucleos(t)ides and immune stimulant for treatment of chronic hepatitis B
$610,511Larisa Y Poluektova · University Of Nebraska Medical Center · R01 · FY2022 · AI
OVERCOMING THE PROTECTIVE BARRIERS OF BREAST CANCER IN BONE MARROW WITH TARGETED PRODRUG NANOTHERAPY
$610,502Gregory M Lanza · Washington University · R01 · FY2022 · CA
Implications of HIV in Low HCV Clearance in Chinese IDUs
$610,488Xiao-Fang Yu · Johns Hopkins University · R01 · FY2007 · DA
2/3 COMpAAAS Tripartite: ART-CC, KP, and VA
$610,414Michael J Silverberg · Kaiser Foundation Research Institute · U01 · FY2020 · AA
Neutralization Fingerprinting Analysis of Polyclonal Antibody Responses against HIV-1
$610,412Ivelin Georgiev · Vanderbilt University Medical Center · R01 · FY2021 · AI